News | Cardiovascular Ultrasound | October 13, 2020

GE Healthcare Receives FDA Clearance for AI-powered Cardiovascular Ultrasound System

The Vivid Ultra Edition, AI-powered cardiovascular ultrasound system is designed to shorten diagnostic exam time and improve measurement consistency

The Vivid Ultra Edition, AI-powered cardiovascular ultrasound system is designed to shorten diagnostic exam time and improve measurement consistency

October 13, 2020 — GE Healthcare announced U.S. FDA 510k clearance for its Ultra Edition package on Vivid cardiovascular ultrasound systems, which includes new features based on artificial intelligence (AI) that enable clinicians to acquire faster, more repeatable exams consistently.

Methodical assessments of heart function are key in echocardiography but can be tedious and timeconsuming to acquire. High quality data acquisition and operator skill are key elements to achieve accurate and complete exams. And, as patients undergo subsequent monitoring exams, the reproducibility of exam assessments is key to identifying improvement or disease progression. Vivid Ultra Edition brings increased efficiencies to the scanning process for reduced exam time through up to 80% fewer clicks, 99% accuracy and less inter-operator variability. 

“We use AI Auto Measure – 2D, AI Auto Measure – Spectrum Recognition, and Auto AFI together with Auto EF. We also use Scan Assist Pro, 4D biplane and 4D triplane. All of this in combination has saved us 7 to 10 minutes per scan, which is fantastic, so we really do have more time to spend with the patient,” said Rebecca Perry, Ph.D., Cardiac Sonography Program Stream Coordinator, University of South Australia, in a Vivid Talk webinar.

Vivid Ultra Edition features leverage AI-driven, neural network-based algorithms designed to deliver repeatable and faster measurements in 2-D echo imaging:

• AI Auto Measure – Spectrum Recognition can semi-automatically detect the appropriate measurement of spectral Doppler images, enabling the system to fast-forward the path from scanning to measurements with 98% accuracy and 100% reproducibility. 

• AI Auto Measure – 2-D can detect the relevant points in the image used to derive key measurements of the left ventricle, performing comparable to human users with 100% reproducibility. 

• AI-based View Recognition can automatically detect with 99% accuracy and 100% reproducibility which standard 2D scan plane is acquired and store this label in the image file. Our AFI package is designed to use these data to automatically select views for strain analysis, streamlining workflow and increasing efficiency.  

“With the Vivid Ultra Edition, we offer AI capabilities that help address healthcare providers’ two key challenges in echo exams – how time consuming the exam is and the degree of variability that exists in the quantitative results,” said Dagfinn Saetre, General Manager of Cardiovascular Ultrasound at GE Healthcare. “This package supports our vision of where we need to go with cardiovascular ultrasound: tools to support less variability and improved productivity. The Vivid Ultra Edition is a solid step in our strategic roadmap.” Vivid Ultra Edition also provides uncompromised image quality and advanced visualization and navigation capabilities:

• HD Color displays anatomy and jet using shadowing, reflections and transparency to enhance the 3-D perception.

• FlexiLight offers photorealistic images to help improve visualization of moving structures and depth perception of tissues.

• 4-D TTE Pediatric probe (6VDc) provides excellent 2-D and 4-D imaging for a range of pediatric patients from neonates to teenagers.

For more information: gevividultraedition.com/3d-map

Related Content

Lesion was originally reported as indeterminate enhancing mass, and outside report recommended biopsy. Classic features of benign hemangioma are shown. Error was attributed to faulty reasoning. A, Axial MR image obtained 5 minutes after contrast agent administration shows peripheral nodular discontinuous enhancement. B, Axial MR image obtained 10 minutes after contrast agent administration shows centripetal progression of enhancement (arrow). C, Axial fast imaging employing steady-state acquisition (FIESTA)

Lesion was originally reported as indeterminate enhancing mass, and outside report recommended biopsy. Classic features of benign hemangioma are shown. Error was attributed to faulty reasoning. A, Axial MR image obtained 5 minutes after contrast agent administration shows peripheral nodular discontinuous enhancement. B, Axial MR image obtained 10 minutes after contrast agent administration shows centripetal progression of enhancement (arrow). C, Axial fast imaging employing steady-state acquisition (FIESTA) MR image shows lesion is homogeneously hyperintense compared with liver parenchyma. Image courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | Magnetic Resonance Imaging (MRI) | October 21, 2020
October 21, 2020 — According to an artic...
According to an inquest, a man with a heart disorder and chest pain died two days after a doctor viewed the wrong scan and sent him home
News | Computed Tomography (CT) | October 21, 2020
October 21, 2020 — The BBC News
Flowchart of patient inclusion and exclusion.

Figure 1. Flowchart of patient inclusion and exclusion.

News | Coronavirus (COVID-19) | October 20, 2020
October 20, 2020 — A new multi-institutional study published in the journal ...
Rensselaer, First-Imaging, and GE Global researchers develop a deep neural network to perform nearly as well as more complex dual-energy CT imaging technology
News | Computed Tomography (CT) | October 20, 2020
October 20, 2020 — Bioimaging technologies are the eyes that allow doctors to see inside the body in order to diagnos
Lesion was originally reported as indeterminate enhancing mass, and outside report recommended biopsy. Classic features of benign hemangioma are shown. Error was attributed to faulty reasoning. A, Axial MR image obtained 5 minutes after contrast agent administration shows peripheral nodular discontinuous enhancement. B, Axial MR image obtained 10 minutes after contrast agent administration shows centripetal progression of enhancement (arrow). C, Axial fast imaging employing steady-state acquisition (FIESTA)

56-Year-Old Woman With Benign Hemangioma: Lesion was originally reported as indeterminate enhancing mass, and outside report recommended biopsy. Classic features of benign hemangioma are shown. Error was attributed to faulty reasoning. A, Axial MR image obtained 5 minutes after contrast agent administration shows peripheral nodular discontinuous enhancement. B, Axial MR image obtained 10 minutes after contrast agent administration shows centripetal progression of enhancement (arrow). C, Axial fast imaging employing steady-state acquisition (FIESTA) MR image shows lesion is homogeneously hyperintense compared with liver parenchyma.

News | Magnetic Resonance Imaging (MRI) | October 16, 2020
October 16, 2020 — 
Carestream Health will offer insights on technology, innovative new products and research in medical imaging through a new webinar series titled Carestream Talks. #RSNA20
News | Radiology Education | October 14, 2020
October 14, 2020 — Carestrea